Absolutely. Structural biology plays a pivotal role in drug development by providing detailed insights into the binding sites of target proteins. This information is crucial for designing drugs that can specifically bind to these sites, thereby inhibiting the function of cancer-causing proteins. Drugs such as imatinib (for chronic myeloid leukemia) and vemurafenib (for BRAF-mutant melanoma) were developed using structural biology techniques.
